NephroSant Publishes Real-World Evidence Showing Potential to Improve the Detection of Early Rejection Events with QSant
/PRNewswire/ -- NephroSant™ a biotechnology company dedicated to accelerating the diagnosis of early kidney damage in native and transplanted kidneys, with a...
Minnie Sarwal Brian Talbert Gina Ford Centers For Medicare Medicaid Services Nephrosant Early Access Program Laboratory Developed Test
Source: prnewswire.com